CLINICAL EVALUATION OF CHILDREN DIAGNOSED WITH SYDENHAM CHOREA, SINGLE CENTER EXPERIENCE Hüseyin PÜR

Mehmet CANPOLAT, Ümmü Gülsüm ÖZGÜL GÜMÜŞ, Hüseyin PER, Süreyya Burcu Görkem, Ali BAYKAN, Hakan GÜMÜŞ

INTRODUCTION

Sydenham chorea (SC) is the definition of rapid, involuntary, short-term, irregular movements involving the distal limbs, face and tongue that occur after Acute Rheumatic Fever (ARF) secondary to throat infection caused by group A betahemolytic streptococci. However, it can also give clinical findings with some emotional conditions such as mood disorders. Deterioration occurs in the patients' skills such as speaking, walking, writing, and buttoning, which affect the quality of their daily life. This can sometimes last for weeks. Although the incidence of ARF has decreased, it is still an important public health problem as a cause of morbidity in developing countries including our country. There are primary and secondary prophylaxis protocols for ARF, but a consensus has not yet been established for the treatment of SC. In the treatment of chorea, in addition to ARF treatment, treatments such as bed rest, haloperidol, carbamazepine, valproic acid, steroid, intravenous immunoglobulin and plasmapheresis are applied.

OBJECTIVES:

Although the incidence of SC has decreased significantly, especially in developed regions, it remains the most common cause of acute chorea in children worldwide. Our aim is to contribute to the literature by retrospectively examining the demographic, clinical, laboratory and imaging findings, recurrence and treatments of the patients.

MATERIALS AND METHODS

The study was carried out with the participation of 268 SC patients who applied to the Erciyes University Pediatric Neurology clinic between 1998-2020. All data were anonymized before analysis. Appropriate statistical tests were performed including normality, descriptive, prescriptive, cathegorical, subgroup and continuous data analysis in PRISM (Graphpad Software Inc., Version 9.0.1.). A p-value < 0.05 was considered significant.

RESULTS

The female/male ratio of the patients was 2:1, and the mean age was $11,3\pm2,3$. The rate of those who heard a murmur at the first admission of the cases was %57,8. Generalized chorea was found in %73,8 of the cases, and hemichorea in %26,2. Carditis was not detected in %3 of the cases. The most common lesion in the ECO findings of the patients was mitral regurgitation with a rate of %96.

		Recurrence					
		Present		Absent		p	
		n	%	n	%		
Gender	Male	9	20.9	81	36	0.076	
	Female	34	79.1	144	64		
Family history	Present	0	0	10	100	0.158	
	Absent	43	100	215	0		
Consanguinity	Present	5	8.9	25	30.1	0.163	
between parents	Absent	51	90.9	58	69.9		
Location	Village	6	13.9	45	20	0.354	
	City	37	86.1	180	80		
Generalized	Present	28	14.1	170	85.9	0.16	
chorea							
Right	Present	6	15.7	32	84.3		
hemichorea							
Left	Present	9	28.1	23	81.9		
hemichorea							
ASO	Normal	3	9.7	16	12.9	0.624	
	Abnormal	28	90.3	108	87.1		
Sedimentation	Normal	22	66.9	93	55.1	0.216	
	Abnormal	11	33.3	76	44.9		
CRP	Normal	25	80.6	86	68.8	0.192	
	Abnormal	6	19.4	39	31.2		
Carditis	Present	42	97.7	218	96.9	0.781	
	Absent	1	2.3	7	3.1		
MRI	Normal	22	75.9	40	67.8	0.435	
	Abnormal	7	24,1	19	32,2		
Application deadline (Days)		51.3 ± 84.3		21.9 ± 39.8		<0.001	
Duration of treatment at		206 ± 182.9		132.3 ± 146.8		<0.001	
first disease (Days)							

ICNC 17th INTERNATIONAL CHILD **NEUROLOGY CONGRESS** ANTALYA, TURKEY | OCTOBER 3-7, 2022

The mean drug response time of the patients was $10,5\pm6,4$ days. The mean duration of treatment at the first disease was 144,2±155,2 days. The mean treatment duration (with or without relapse) in patients with haloperidol monotherapy was 146,4 \pm 176,1 days, while the mean treatment duration was 280,9±263,2 days in patients using single or combined drug regiment other than haloperidol (**p=<0.001**).

The mean duration of treatment for non-relapsed patients was $132,3\pm146,8$ days, while the mean treatment time for relapsed patients at the first disease was 206±182,9 days (**p** <**0.001**).

Recurrence was observed in %16.1 of the cases. The first recurrences were seen after a mean of 13,6±20,6 months. A significant correlation was found between the time between the onset of symptoms and admission to the hospital and the recurrence of chorea. It was determined that the frequency of recurrence increased as the application time increased (p<0.001).

There was no statistically significant difference for recurrence between relapsed and non-relapsed patients about age, gender, family history of SC, consanguinity between parents, place of origin of the cases, presence of generalized or hemichorea, presence of carditis, CRP/ASO/ESH elevation, normal or abnormal MRI

CONCLUSIONS

Sydenham's chorea is still an important public health problem in our country. It has been concluded that the frequency of relapse increases as the time to apply to the hospital increases, the duration of treatment in the first attack of patients with relapse is longer than those who do not relapse, and the haloperidol treatment is more effective in terms of treatment time compared to other treatments.

REFERENCES

1- Beier K, Pratt DP. Sydenham Chorea - StatPearls - NCBI Bookshelf. 2020;1–2 2- Cardoso F. Sydenham's chorea. Vol. 10, Current Treatment Options in Neurology. 2008. p. 230–5

3- sydenham-chorea @ www.uptodate.com [Internet]. Available from: https://www.-uptodate.com/contents/sydenham-chorea













